Orexo appoints Carl-Johan Blomberg CFO
This article was originally published in Scrip
Carl-Johan Blomberg has joined Orexo, a pharmaceutical company focusing on developing treatments for pain and inflammation, as chief financial officer. Mr Blomberg most recently served as CFO at Micronic Mydata, and has also held financial director positions at Alfa-Laval, Procordia and Pharmacia & Upjohn.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.